Adams execs
This article was originally published in The Tan Sheet
Executive Summary
Helmut Albrecht, MD, joins Adams Respiratory Therapeutics to serve as senior VP-R&D, the firm announces Oct. 29. Albrecht will oversee all R&D activities, including clinical development, regulatory issues and new product development; the new exec said Adams "is ready to expand its presence in the respiratory category." Most recently, Albrecht was Novartis Consumer Health/OTC business unit's VP-global preclinical & clinical development. New VP-Regulatory Affairs Susan Witham will report to Albrecht. Witham previously held senior positions at J&J Consumer and Novartis. The appointments follow Adams' recently announced strategic decision to focus on OTCs and expand the Mucinex line (1"The Tan Sheet" May 31, 2004, p. 9)...
You may also be interested in...
Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs
A major task facing Adams Respiratory Therapeutics' new VP-OTC Marketing & Business Development Robert Casale will be to plan a Fall 2004 launch of extensions to the firm's Mucinex expectorant brand
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.